Ivabradine: A Potential Therapeutic for Children With Refractory SVT

Background: In April 2015, ivabradine was approved by the Food and Drug Administration for the treatment of patients with coronary artery disease and heart failure (HF). The use of this medication has been linked with improved clinical outcomes and reduced rates of hospitalization in patients with s...

Descripción completa

Detalles Bibliográficos
Autores principales: Younis, Nour K., Abi-Saleh, Bernard, Al Amin, Farah, El Sedawi, Omar, Tayeh, Christelle, Bitar, Fadi, Arabi, Mariam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368123/
https://www.ncbi.nlm.nih.gov/pubmed/34414216
http://dx.doi.org/10.3389/fcvm.2021.660855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368123/
https://www.ncbi.nlm.nih.gov/pubmed/34414216
http://dx.doi.org/10.3389/fcvm.2021.660855

Ejemplares similares